نمایش مختصر رکورد

dc.contributor.authorGashlin, Lauren Z.en_US
dc.contributor.authorGroth, Christine M.en_US
dc.contributor.authorWiegand, Timothy J.en_US
dc.contributor.authorAshley, Elizabethen_US
dc.date.accessioned1399-07-09T12:21:52Zfa_IR
dc.date.accessioned2020-09-30T12:21:52Z
dc.date.available1399-07-09T12:21:52Zfa_IR
dc.date.available2020-09-30T12:21:52Z
dc.date.issued2015-03-01en_US
dc.date.issued1393-12-10fa_IR
dc.date.submitted2014-11-17en_US
dc.date.submitted1393-08-26fa_IR
dc.identifier.citationGashlin, Lauren Z., Groth, Christine M., Wiegand, Timothy J., Ashley, Elizabeth. (2015). Comparison of Alcohol Withdrawal Outcomes in Patients Treated with Benzodiazepines Alone versus Adjunctive Phenobarbital: a Retrospective Cohort Study. Asia Pacific Journal of Medical Toxicology, 4(1), 31-36. doi: 10.22038/apjmt.2015.3984en_US
dc.identifier.issn2322-2611
dc.identifier.issn2322-4320
dc.identifier.urihttps://dx.doi.org/10.22038/apjmt.2015.3984
dc.identifier.urihttp://apjmt.mums.ac.ir/article_3984.html
dc.identifier.urihttps://iranjournals.nlai.ir/handle/123456789/420573
dc.description.abstract<em>Background:</em> For treatment of severe alcohol withdrawal syndrome, high dose benzodiazepines (BZDs) may cause delirium and over-sedation. Phenobarbital (PBT) is a long-acting barbiturate effective for the treatment of alcohol withdrawal. Given the potential benefits of PBT, we sought to investigate the effectiveness of PBT as adjunctive treatment for alcohol withdrawal. <br/><em>Methods:</em> This was a retrospective cohort study on patients with a diagnosis of alcohol withdrawal who had a CIWA-Ar score > 10 treated with either BZDs alone (BZD alone group) or BZDs with adjunctive PBT (PBT-adjunct group). The patients received at least one dose of PBT in addition to BZDs (variable doses) in the PBT-adjunct group, and three doses of 20 mg diazepam equivalents within 6 hours in the BZD alone group. The primary endpoint was the proportion of patients with a CIWA-Ar score < 10 at 24 hours after initial treatment. Duration of withdrawal and cumulative dose of BZDs were also assessed. <br/><em>Results:</em> Seven subjects in the adjunctive phenobarbital and 21 in the benzodiazepine group were included in the final analysis. Two patients (28.6%) in the PBT-adjunct group and 5 patients (23.8%) in the BZD only group achieved the primary endpoint, though the difference between the two groups was not statistically significant (P = 0.588). The median (IQR) duration of withdrawal symptoms was 44 (12-62) hours in the PBT-adjunct group compared to 53 (37-87) hours in the BZD only group, with no significant difference between the groups (P = 0.249). The median (IQR) cumulative BZD dose requirement (diazepam equivalent) in the PBT-adjunct group was significantly lower than BZD alone group (25 (20-226) vs. 326 (160-550) mg, P = 0.02). <br/><em>Conclusion:</em> PBT appears to be a safe and effective alternative to BZDs for the treatment of alcohol withdrawal in non-critically ill patients and may be BZD sparing.en_US
dc.format.extent609
dc.format.mimetypeapplication/pdf
dc.languageEnglish
dc.language.isoen_US
dc.publisherMashhad University of Medical Sciencesen_US
dc.relation.ispartofAsia Pacific Journal of Medical Toxicologyen_US
dc.relation.isversionofhttps://dx.doi.org/10.22038/apjmt.2015.3984
dc.subjectAlcohol Withdrawal Deliriumen_US
dc.subjectAlcoholismen_US
dc.subjectBenzodiazepinesen_US
dc.subjectComparative Effectiveness Researchen_US
dc.subjectPhenobarbitalen_US
dc.titleComparison of Alcohol Withdrawal Outcomes in Patients Treated with Benzodiazepines Alone versus Adjunctive Phenobarbital: a Retrospective Cohort Studyen_US
dc.typeTexten_US
dc.typeOriginal Articleen_US
dc.contributor.departmentDepartment of Pharmacy, University of Rochester Medical Center, Rochester, USAen_US
dc.contributor.departmentDepartment of Pharmacy, University of Rochester Medical Center, Rochester, USAen_US
dc.contributor.departmentDepartment of Emergency Medicine, University of Rochester Medical Center, Rochester, USAen_US
dc.contributor.departmentDepartment of Pharmacy, University of Rochester Medical Center, Rochester, USAen_US
dc.citation.volume4
dc.citation.issue1
dc.citation.spage31
dc.citation.epage36


فایل‌های این مورد

Thumbnail

این مورد در مجموعه‌های زیر وجود دارد:

نمایش مختصر رکورد